Measurement of serum antibodies against NY-ESO-1 by ELISA: A guide for the treatment of specific immunotherapy for patients with advanced colorectal cancer

NY-ESO-1 has been identified as one of the most immunogenic antigens; thus, is a highly attractive target for cancer immunotherapy. The present study analyzed the expression of serum antibodies (Abs) against NY-ESO-1 in patients with advanced colorectal cancer (CRC), with the aim of guiding the trea...

Full description

Saved in:
Bibliographic Details
Published in:Experimental and therapeutic medicine 2014-10, Vol.8 (4), p.1279-1284
Main Authors: LONG, YAN-YAN, WANG, YU, HUANG, QIAN-RONG, ZHENG, GUANG-SHUN, JIAO, SHUN-CHANG
Format: Article
Language:English
Subjects:
Antibodies
antigen-specific immunotherapy
Antigens
Colorectal cancer
Diagnosis
Drug therapy
Enzyme-linked immunosorbent assay
Health aspects
humoral immunity
Immunoglobulins
Immunotherapy
Lymphatic system
Measurement
Metastasis
Mortality
NY-ESO-1
Patients
Physiological aspects
serum antibody
Statistical analysis
Tumors
Viral antibodies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:NY-ESO-1 has been identified as one of the most immunogenic antigens; thus, is a highly attractive target for cancer immunotherapy. The present study analyzed the expression of serum antibodies (Abs) against NY-ESO-1 in patients with advanced colorectal cancer (CRC), with the aim of guiding the treatment of NY-ESO-1-based specific-immunotherapy for these patients. Furthermore, the present study was the first to evaluate the kinetic expression of anti-NY-ESO-1 Abs and investigate the possible influencing factors. A total of 239 serum samples from 155 pathologically confirmed patients with advanced CRC (stages III and IV) were collected. The presence of spontaneous Abs against NY-ESO-1 was analyzed using an enzyme-linked immunosorbent assay (ELISA). The results demonstrated that 24.5% (38/155) of the investigated patients were positive for NY-ESO-1-specific Abs. No statistically significant correlations were identified between the expression of anti-NY-ESO-1 Abs and clinicopathological parameters, including age and gender, location, grading, local infiltration, lymph node status, metastatic status and K-ras mutation status (P>0.05). In 59 patients, the kinetic expression of anti-NY-ESO-1 Abs was analyzed, of which 14 patients were initially positive and 45 patients were initially negative. Notably, 16/59 (27.1%) patients changed their expression status during the study period, and the initially positive patients were more likely to change compared with the initially negative patients (85.7 vs. 8.8%; P
ISSN:1792-0981
1792-1015
DOI:10.3892/etm.2014.1913